Gynecol Oncol (2005) 97(3):8708
This is one of those areas that were exploring as a group, and one of the ways that we approach these complicated patients
Priyali Singh, MD The semaglutide patent expiry biosimilar question is no longer hypothetical
Semaglutide, StatPearls (2024) Ozempic drug label, DailyMed (2023) Tendency of semaglutide to induce gastroparesis: A case report, Cureus (2024) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes, Obesity, and Metabolism (2022) Switching between glucagon-like peptide-1 agonists: Rationale and practical guidance, Clinical Diabetes (2020) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
In this study, we elucidate the mechanism by which reduced lithocholic acid suppresses glucagon-like peptide 1 via farnesoid X receptor activation under high-temperature and humidity condition